Does the behavior of Crohn's disease change over time? by Louis, Edouard et al.
Does the behaviour of Crohn’s disease change over time?

Edouard Louis, Catherine Reenaers, Jacques Belaiche. 






The behaviour of Crohn’s disease (CD) is usually defined by the development of fistulising or stricturing lesions (1). Early lesions of CD are thought to be superficial aphtoid lesions. If the intensity of the inflammation increases, the lesions may become deeper and transmural. The reason why in some patients this transmural inflammatory process will involve muscular propria layer with fibrosis and smooth muscle cells hyperplasia giving rise to stricture or dissect this layer to give rise to penetrating lesions is unknown. It could be “by chance”, driven by circumstantial external factors. However, two facts are against this unique hypothesis and suggest an innate inclination potentially genetically determined: a) there is a significant concordance among multiply affected families (2) and among monozygotic twins (3) for the development of such lesions, b) a given patient tends to develop the same type of lesion after surgical resection of intestinal segments (4). If we consider these facts, we could conclude that there is a fixed disease behaviour in a given patient and that it does not change over time. However that is not that simple, since these lesions will develop with time (5, 6). If we try to classify a patient at a given time point over the course of the disease he or she may fall into anyone of the three categories “nonstricturing nonpenetrating, stricturing or penetrating”, even if he or she has a fixed inclination to develop another type of lesion. If we have to classify the same patient a few years later, he or she may fall into another category. Practically, at diagnosis, more than 70% of the patients present with a pure inflammatory behaviour, while a bit more than 10% have a stricturing behaviour and a similar proportion penetrating behaviour (5). Ten years later about one third of the patients have developed penetrating lesions and one other third pure stricturing lesions. Thereafter, the proportion of patients with pure stricturing lesions tends to remain stable, while penetrating lesions progressively increase to reach up to 50% after 20 years (5).  These considerations may have impact both on clinical and pathophysiological aspects.
From a clinical point of view it is very important to know what type of lesions are present at a given time point to help and decide the therapeutic strategy. Indeed inflammatory, stricturing or penetrating lesions do not respond to treatment the same way. The drugs we have currently to treat CD, are essentially active on the inflammatory lesions. The effect infliximab and to a lesser extent immunosuppressants have on fistulising disease is probably related to their powerful control of inflammatory process which may secondarily allow scaring of fistulous tracks, the healing of these tracks being much slower than the control of inflammation and the scaring of mucosal lesions. As far as stricturing lesions, no treatment has proven effective so far. On the other hand, when discussing long term therapeutic strategy, it may be important to know the inclination  for developing stricturing or penetrating lesions because this may lead to more aggressive maintenance treatment to avoid such complication, although no controlled data has really proven the efficacy of such preventive treatment. This inclination may be a stable trait and may be inferred from the past history and to some extent the family history of the patient (2-4).
From a pathophysiological point of view, understanding the mechanisms that underlie the development of stricturing and penetrating complications is important because it may help to subclassify CD, which would probably help to understand the bases of the disease. The difficulty here is that, as the disease itself, the behaviour of CD is most probably a multifactorial polygenic character. The factor for which an influence on disease behaviour is the clearest is probably disease location (7, 8). Ileal CD has been associated to the development of both stricturing and intraabdominal penetrating lesions. The calibre of the ileum, which is smaller than the colon, and the role of the ileo-caecal valve are suspected in this phenomenon. Immunology and microflora of the ileum are also different from the one of the colon. The anal canal is also a common place for CD stricture and fistulae often arise just upward from the low rectum or  the proximal anal canal. Globally it is rather rare to find a fistula in CD that is not associated with a downward stricture (9). The mechanism could be an increase in luminal pressure favouring penetrating lesions developing from transmural inflammation. Although some genes have been suggested to be associated with CD behaviour in isolated studies none has really been confirmed on a large scale and with convincing methods of analysis. Smoking has been associated in some studies with the development of penetrating lesions (8,10). Treatment could also have an influence. However there is no prospective controlled data to substantiate this.
In conclusion, objectively, CD behaviour does change over time. Therefore, when a treatment has to be decided or when a patient has to be classified for genetic or epidemiologic studies an evaluation must determine whether at a given time point there is or not stricturing or penetrating lesions. On the other hand, there may also be an inclination to develop either type of lesions. This may be a stable trait, potentially partly genetically determined. However, this stable trait may rather influence the speed at which and the probability with which the stricturing of penetrating lesions will develop.
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